TW201613922A - Macrocycles with aromatic P2' groups as factor XIA inhibitors - Google Patents

Macrocycles with aromatic P2' groups as factor XIA inhibitors

Info

Publication number: TW201613922A
Authority: TW; Taiwan
Prior art keywords: factor xia; macrocycles; aromatic; groups; xia inhibitors
Prior art date: 2014-01-31

Application number

TW104103305A

Other languages

English (en)

Inventor

James R Corte

Indawati Delucca

Tian-An Fang

Wu Yang

Yu-Feng Wang

Andrew K Dilger

Kumar Balashanmuga Pabbisetty

William R Ewing

Yeheng Zhu

Ruth R Wexler

Donald J Pinto

Michael J Orwat

Leon M Ii Smith

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-01-31

Filing date

2015-01-30

Publication date

2016-04-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52484570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW201613922(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-01-30 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2016-04-16 Publication of TW201613922A publication Critical patent/TW201613922A/zh

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Compression Or Coding Systems Of Tv Signals (AREA)

TW104103305A 2014-01-31 2015-01-30 Macrocycles with aromatic P2' groups as factor XIA inhibitors TW201613922A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201461933942P	2014-01-31	2014-01-31
US201462058293P	2014-10-01	2014-10-01

Publications (1)

Publication Number	Publication Date
TW201613922A true TW201613922A (en)	2016-04-16

Family

ID=52484570

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
TW104103366A TWI688564B (zh)	2014-01-31	2015-01-30	作為凝血因子ｘｉａ抑制劑之具有雜環p2'基團之巨環化合物
TW111149560A TWI859674B (zh)	2014-01-31	2015-01-30	作為凝血因子xia抑制劑之具有雜環p2'基團之巨環化合物
TW109105925A TWI790421B (zh)	2014-01-31	2015-01-30	作為凝血因子xia抑制劑之具有雜環p2'基團之巨環化合物
TW104103305A TW201613922A (en)	2014-01-31	2015-01-30	Macrocycles with aromatic P2' groups as factor XIA inhibitors

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
TW104103366A TWI688564B (zh)	2014-01-31	2015-01-30	作為凝血因子ｘｉａ抑制劑之具有雜環p2'基團之巨環化合物
TW111149560A TWI859674B (zh)	2014-01-31	2015-01-30	作為凝血因子xia抑制劑之具有雜環p2'基團之巨環化合物
TW109105925A TWI790421B (zh)	2014-01-31	2015-01-30	作為凝血因子xia抑制劑之具有雜環p2'基團之巨環化合物

Country Status (32)

Country	Link
US (2)	US20170002006A1 (zh)
EP (4)	EP3988549A1 (zh)
JP (6)	JP6464176B2 (zh)
KR (3)	KR20240017118A (zh)
CN (4)	CN110845498B (zh)
AU (5)	AU2015210904C1 (zh)
BR (1)	BR112016015717B1 (zh)
CA (1)	CA2937739C (zh)
CL (1)	CL2016001933A1 (zh)
CY (1)	CY1120702T1 (zh)
DK (1)	DK3099687T3 (zh)
EA (1)	EA030222B1 (zh)
ES (3)	ES2687498T3 (zh)
HR (1)	HRP20181339T1 (zh)
HU (1)	HUE040226T2 (zh)
IL (5)	IL307212A (zh)
LT (1)	LT3099687T (zh)
MX (2)	MX377545B (zh)
MY (1)	MY190429A (zh)
NZ (2)	NZ761182A (zh)
PE (2)	PE20210470A1 (zh)
PH (2)	PH12016501249B1 (zh)
PL (1)	PL3099687T3 (zh)
PT (1)	PT3099687T (zh)
RS (1)	RS57659B1 (zh)
SG (2)	SG11201606209PA (zh)
SI (1)	SI3099687T1 (zh)
SM (1)	SMT201800505T1 (zh)
TW (4)	TWI688564B (zh)
UY (3)	UY35971A (zh)
WO (2)	WO2015116886A1 (zh)
ZA (1)	ZA201606011B (zh)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201116559D0 (en)	2011-09-26	2011-11-09	Univ Leuven Kath	Novel viral replication inhibitors
PL2766346T3 (pl)	2011-10-14	2017-09-29	Bristol-Myers Squibb Company	Podstawione związki tetrahydroizochinoliny jako inhibitory czynnika XIA
JP6479763B2 (ja)	2013-03-25	2019-03-06	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
ES2687498T3 (es) *	2014-01-31	2018-10-25	Bristol-Myers Squibb Company	Macrociclos con grupos P2¿ heterocíclicos como inhibidores del factor XIa
NO2760821T3 (zh)	2014-01-31	2018-03-10
EP2913330A1 (en)	2014-02-27	2015-09-02	Laboratoire Biodim	Condensed derivatives of imidazole useful as pharmaceuticals
ES2714283T3 (es)	2014-09-04	2019-05-28	Bristol Myers Squibb Co	Macrociclos de diamida que son inhibidores de FXIa
NO2721243T3 (zh) *	2014-10-01	2018-10-20
US9453018B2 (en)	2014-10-01	2016-09-27	Bristol-Myers Squibb Company	Pyrimidinones as factor XIa inhibitors
NZ730981A (en)	2014-10-01	2024-01-26	Merck Patent Gmbh	Boronic acid derivatives
JOP20160086B1 (ar)	2015-05-08	2021-08-17	2 Katholieke Univ Leuven Ku Leuven Research And Development	مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
US10160750B2 (en)	2015-06-19	2018-12-25	Bristol-Myers Squibb Company	Diamide macrocycles as factor XIa inhibitors
JO3703B1 (ar)	2015-07-09	2021-01-31	Bayer Pharma AG	مشتقات أوكسوبيريدين مستبدلة
CN107849026B (zh)	2015-07-29	2021-01-01	百时美施贵宝公司	携带烷基或环烷基p2′部分的因子xia大环抑制剂
CN107922393A (zh)	2015-07-29	2018-04-17	百时美施贵宝公司	携带非芳族p2,基团的因子xia新大环
JOP20160198B1 (ar)	2015-09-16	2022-03-14	Janssen Pharmaceuticals Inc	مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar)	2015-09-16	2020-08-27	Katholieke Univ Leuven Ku Leuven Research & Development	مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CA2998902C (en) *	2015-10-29	2024-03-26	Merck Sharp & Dohme Corp.	Macrocyclic compounds as factor xia inhibitors
WO2017074833A1 (en)	2015-10-29	2017-05-04	Merck Sharp & Dohme Corp.	Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use
WO2017151746A1 (en)	2016-03-02	2017-09-08	Bristol-Myers Squibb Company	Diamide macrocycles having factor xia inhibiting activity
HUE054936T2 (hu)	2016-03-31	2021-10-28	Janssen Pharmaceuticals Inc	Helyettesített indol-származékok mint a dengue-vírus replikációjának inhibitorai
EA201892216A1 (ru)	2016-03-31	2019-03-29	Янссен Фармасьютикалз, Инк.	Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
US10730884B2 (en)	2016-04-01	2020-08-04	Janssen Pharmaceuticals, Inc.	Substituted indole compound derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar)	2016-04-01	2021-08-17	1 Janssen Pharmaceuticals Inc	مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AR109304A1 (es)	2016-08-10	2018-11-21	Sumitomo Chemical Co	Compuesto de oxadiazol y su uso
WO2018039094A1 (en)	2016-08-22	2018-03-01	Merck Sharp & Dohme Corp.	Pyridine-1-oxide derivatives and their use as factor xia inhibitors
CN110062757B (zh) *	2017-01-18	2022-03-04	广东东阳光药业有限公司	凝血因子XIa抑制剂及其用途
JOP20180025B1 (ar)	2017-03-31	2021-08-17	Janssen Pharmaceuticals Inc	مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar)	2017-03-31	2019-01-30	Univ Leuven Kath	مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
UA125970C2 (uk)	2017-05-22	2022-07-20	Янссен Фармасьютікалз, Інк.	Заміщені похідні індоліну як інгібітори реплікації вірусів денге
US11407715B2 (en)	2017-05-22	2022-08-09	Janssen Pharmaceuticals, Inc.	Substituted indoline derivatives as dengue viral replication inhibitors
WO2019011166A1 (zh) *	2017-07-14	2019-01-17	四川科伦博泰生物医药股份有限公司	大环酰胺化合物及其药物组合物和用途
BR112021020257A2 (pt) *	2019-04-11	2021-12-07	Bristol Myers Squibb Co	Desempenho intensificado de sólido amorfo e formulações solubilizadas para realizar concentrações de plasma terapêutico
MX2021012286A (es)	2019-04-11	2022-04-06	Bristol Myers Squibb Co	Nuevas opciones sinteticas hacia la manufactura de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6 -oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-he xahidro-11,15-(meteno)pirazol[4,3-b][1,7]diazaciclotetradecin-5(6 h)-ona.
CN113677682B (zh) *	2019-04-16	2023-05-30	华润生物医药有限公司	作为XIa因子抑制剂的大环衍生物
WO2021013209A1 (zh)	2019-07-23	2021-01-28	南京明德新药研发有限公司	作为XIa因子抑制剂的大环衍生物
TWI749881B (zh) *	2019-11-21	2021-12-11	大陸商深圳信立泰藥業股份有限公司	二氧代哌類衍生物、其製備方法及其在醫藥上的應用
CA3179957A1 (en) *	2020-04-10	2021-10-14	Bristol-Myers Squibb Company	Crystalline forms of (9r,13s)-13-{4-[5-chloro-2-(4-chloro-1h,2,3-triazol- 1 -yl)phenyl]-6-oxo-1,6-dihydropyrimidin- 1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricy clo[12.3.1.02·6]octadeca- 1(18),2(6),4,14,16-pentaen-8-one
TW202229280A (zh) *	2020-10-12	2022-08-01	美商必治妥美雅史谷比公司	（６ｒ，１０ｓ）－１０－｛４－［５－氯－２－（４－氯－１ｈ－１，２，３－三唑－１－基）苯基］－６－側氧基－１（６ｈ）－嘧啶基｝－１－（二氟甲基）－６－甲基－１，４，７，８，９，１０－六氫－１１，１５－（亞甲橋基）吡唑并［４，３－ｂ］［１，７］二氮雜環十四炔－５（６ｈ）－酮之製備方法
JP7517964B2 (ja) *	2020-11-27	2024-07-17	シャープ株式会社	電子機器、電子機器の制御方法、プログラム、記録媒体
CN112608274B (zh) *	2020-12-30	2022-09-06	西南大学	一种手性胺化合物的催化合成方法及其化合物
MX2023008142A (es) *	2021-01-08	2023-09-08	Bristol Myers Squibb Co	Anticuerpos y péptidos de unión a antígenos para inhibidores del factor xia y usos de los mismos.
CN112876461B (zh) *	2021-01-20	2022-12-30	上海零诺生物科技有限公司	尼古丁及其中间体的制备方法
CN117603208A (zh) *	2021-04-21	2024-02-27	上海美悦生物科技发展有限公司	FXIa抑制剂及其药物组合物、制备方法和用途
CN118973564A (zh) *	2022-02-03	2024-11-15	D·E·萧尔研究有限责任公司	作为trpa1抑制剂的哒嗪酮化合物
CA3258449A1 (en) *	2022-06-08	2023-12-14	Blossomhill Therapeutics, Inc.	INDAZOLE MACROCYCLES AND THEIR USE
WO2025002297A1 (zh) *	2023-06-30	2025-01-02	深圳信立泰药业股份有限公司	一种多取代的大环化合物及其制备方法与应用
WO2025224678A1 (en)	2024-04-25	2025-10-30	Assia Chemical Industries Ltd.	Solid state forms of milvexian and process for preparation thereof

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR1525186A (fr)	1967-03-29	1968-05-17	Roussel Uclaf	Nouvelles pénicillines et procédé de préparation
EP0028489B1 (en)	1979-11-05	1983-10-05	Beecham Group Plc	Enzyme derivatives, and their preparation
DE4034829A1 (de)	1990-11-02	1992-05-07	Merck Patent Gmbh	Cyclopeptide
JP3190431B2 (ja)	1991-07-01	2001-07-23	三菱化学株式会社	ケトン誘導体
GB9206757D0 (en)	1992-03-27	1992-05-13	Ferring Bv	Novel peptide receptor ligands
US5624936A (en)	1995-03-29	1997-04-29	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
WO1996034010A2 (en)	1995-03-29	1996-10-31	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
AU717298B2 (en)	1996-04-03	2000-03-23	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5869682A (en)	1996-04-03	1999-02-09	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
PE121699A1 (es)	1997-02-18	1999-12-08	Boehringer Ingelheim Pharma	Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en)	1997-06-19	1999-12-17	Du Pont Merck Pharma	Guanidine mimics as factor Xa inhibitors.
TW557297B (en)	1997-09-26	2003-10-11	Abbott Lab	Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
ID27002A (id)	1998-03-19	2001-02-22	Vertex Pharma	Penghambat-penghambat kaspase
EE200000706A (et)	1998-05-26	2002-06-17	Warner-Lambert Company	Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid
US6307049B1 (en)	1998-09-30	2001-10-23	The Procter & Gamble Co.	Heterocyclic 2-substituted ketoamides
CN1332734A (zh)	1999-01-02	2002-01-23	阿文蒂斯药物德国有限公司	新颖的丙二酸衍生物、其制备方法、其用途和含有它们的药物组合物(Xa因子活性抑制作用
EP1016663A1 (en)	1999-01-02	2000-07-05	Aventis Pharma Deutschland GmbH	Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity)
IL145771A0 (en)	1999-04-09	2002-07-25	Basf Ag	Low-molecular inhibitors of complement proteases
WO2000076970A2 (en)	1999-06-14	2000-12-21	Eli Lilly And Company	Serine protease inhibitors
DE19962924A1 (de)	1999-12-24	2001-07-05	Bayer Ag	Substituierte Oxazolidinone und ihre Verwendung
EP1125925A1 (en)	2000-02-15	2001-08-22	Applied Research Systems ARS Holding N.V.	Amine derivatives for the treatment of apoptosis
CN1244561C (zh)	2000-05-11	2006-03-08	布里斯托尔-迈尔斯斯奎布公司	可用作生长激素促分泌素的四氢异喹啉类似物
SV2003000617A (es)	2000-08-31	2003-01-13	Lilly Co Eli	Inhibidores de la proteasa peptidomimetica ref. x-14912m
AR035216A1 (es)	2000-12-01	2004-05-05	Astrazeneca Ab	Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AU2002322802A1 (en) *	2001-07-27	2003-02-17	Merck And Co., Inc.	Thrombin inhibitors
US6951840B2 (en)	2001-08-31	2005-10-04	Eli Lilly And Company	Lipoglycopeptide antibiotics
GEP20074098B (en)	2001-09-21	2007-05-10	Bristol Myers Squibb Co	Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US6649606B1 (en)	2001-11-09	2003-11-18	Bristol-Myers Squibb Co.	Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
AU2002316317A1 (en)	2002-06-18	2003-12-31	The Scripps Research Institute	Synthesis of diazonamide "a" core
US20040180855A1 (en)	2003-02-19	2004-09-16	Schumacher William A.	Methods of treating thrombosis with reduced risk of increased bleeding times
US7138412B2 (en)	2003-03-11	2006-11-21	Bristol-Myers Squibb Company	Tetrahydroquinoline derivatives useful as serine protease inhibitors
US7129264B2 (en)	2003-04-16	2006-10-31	Bristol-Myers Squibb Company	Biarylmethyl indolines and indoles as antithromboembolic agents
JP2007501844A (ja)	2003-08-08	2007-02-01	トランス　テック　ファーマ，インコーポレイテッド	アリール及びヘテロアリール化合物、組成物並びに使用方法
US7417063B2 (en)	2004-04-13	2008-08-26	Bristol-Myers Squibb Company	Bicyclic heterocycles useful as serine protease inhibitors
US7429604B2 (en)	2004-06-15	2008-09-30	Bristol Myers Squibb Company	Six-membered heterocycles useful as serine protease inhibitors
US7453002B2 (en)	2004-06-15	2008-11-18	Bristol-Myers Squibb Company	Five-membered heterocycles useful as serine protease inhibitors
EP2457895A1 (en)	2004-07-12	2012-05-30	Idun Pharmaceuticals, Inc.	Tetrapeptide analogs
CN101137412B (zh)	2005-01-13	2012-11-07	布里斯托尔-迈尔斯·斯奎布公司	用作凝血因子XIa抑制剂的取代的二芳基化合物
US20060183771A1 (en)	2005-02-17	2006-08-17	Seiffert Dietmar A	Novel combination of selective factor VIIa and/or factor XIa inhibitors and selective plasma kallikrein inhibitors
US20070111947A1 (en)	2005-10-14	2007-05-17	Mcmurry Thomas J	Fibrin targeted therapeutics
US20070112012A1 (en)	2005-11-11	2007-05-17	Markus Boehringer	Carbocyclic fused cyclic amines
WO2007070816A2 (en)	2005-12-14	2007-06-21	Bristol-Myers Squibb Company	Thiophene derivatives as factor xia inhibitors
EP1966141A1 (en)	2005-12-14	2008-09-10	Brystol-Myers Squibb Company	Six-membered heterocycles useful as serine protease inhibitors
WO2007070826A1 (en)	2005-12-14	2007-06-21	Bristol-Myers Squibb Company	Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
CN101389613B (zh) *	2005-12-23	2011-10-12	布里斯托尔-迈尔斯.斯奎布公司	用作抗凝血药的大环凝血因子viia抑制剂
PE20071132A1 (es)	2005-12-23	2007-12-14	Bristol Myers Squibb Co	Compuestos macrociclicos como inhibidores del factor viia
WO2008076805A2 (en)	2006-12-15	2008-06-26	Bristol-Myers Squibb Company	Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
PE20081775A1 (es)	2006-12-20	2008-12-18	Bristol Myers Squibb Co	Compuestos macrociclicos como inhibidores del factor viia
JP5318094B2 (ja)	2007-06-13	2013-10-16	ブリストル−マイヤーズスクイブカンパニー	凝固因子阻害剤としてのジペプチド類似体
CN102026996B (zh)	2008-03-13	2015-01-07	百时美施贵宝公司	作为凝血因子xia抑制剂的哒嗪衍生物
US8624040B2 (en)	2009-06-22	2014-01-07	Millennium Pharmaceuticals, Inc.	Substituted hydroxamic acids and uses thereof
US8513433B2 (en)	2009-07-02	2013-08-20	Angion Biomedica Corp.	Small molecule inhibitors of PARP activity
EP2462123B1 (en)	2009-08-04	2013-10-02	Merck Sharp & Dohme Corp.	4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
US8952024B2 (en) *	2009-09-09	2015-02-10	E I Du Pont De Nemours And Company	Herbicidal pyrimidone derivatives
US8828983B2 (en) *	2010-02-11	2014-09-09	Bristol-Myers Squibb Company	Macrocycles as factor XIa inhibitors
WO2013009527A2 (en)	2011-07-08	2013-01-17	Merck Sharp & Dohme Corp.	Factor ixa inhibitors
TW201311689A (zh) *	2011-08-05	2013-03-16	必治妥美雅史谷比公司	作為因子ｘｉａ抑制劑之新穎巨環化合物
TW201319068A (zh) *	2011-08-05	2013-05-16	必治妥美雅史谷比公司	作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
PL2766346T3 (pl)	2011-10-14	2017-09-29	Bristol-Myers Squibb Company	Podstawione związki tetrahydroizochinoliny jako inhibitory czynnika XIA
IN2014CN02806A (zh)	2011-10-14	2015-07-03	Bristol Myers Squibb Co
JP6033318B2 (ja)	2011-10-14	2016-11-30	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	第ＸＩａ因子阻害剤としての置換テトラヒドロイソキノリン化合物
DK2794597T3 (en) *	2011-12-21	2018-01-15	Ono Pharmaceutical Co	PYRIDINON AND PYRIMIDINON DERIVATIVES AS FACTOR XIA INHIBITORS
GB2497806A (en)	2011-12-21	2013-06-26	Ono Pharmaceutical Co	Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
US20140378474A1 (en)	2012-01-27	2014-12-25	Novartis Ag	5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
EP2807156A1 (en)	2012-01-27	2014-12-03	Novartis AG	Aminopyridine derivatives as plasma kallikrein inhibitors
JP2015083542A (ja)	2012-02-08	2015-04-30	大日本住友製薬株式会社	３位置換プロリン誘導体
SI2847228T1 (sl)	2012-05-10	2018-11-30	Bayer Pharma Aktiengesellschaft	Protitelesa zmožna vezave na faktor koagulacije XI in/ali njeno aktivirano obliko faktor XIa in njihove uporabe
GB201209138D0 (en)	2012-05-24	2012-07-04	Ono Pharmaceutical Co	Compounds
WO2014014050A1 (ja)	2012-07-19	2014-01-23	大日本住友製薬株式会社	１－（シクロアルキルカルボニル）プロリン誘導体
CA2880898A1 (en)	2012-08-03	2014-02-06	Bristol-Myers Squibb Company	Dihydropyridone p1 as factor xia inhibitors
US9409908B2 (en) *	2012-08-03	2016-08-09	Bristol-Myers Squibb Company	Dihydropyridone p1 as factor XIa inhibitors
EA032092B1 (ru)	2012-10-12	2019-04-30	Бристол-Майерс Сквибб Компани	Кристаллические формы ингибитора фактора xia
US9315519B2 (en)	2012-10-12	2016-04-19	Bristol-Myers Squibb Company	Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
EP2906541B1 (en)	2012-10-12	2017-11-22	Bristol-Myers Squibb Company	Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2934538B1 (en)	2012-12-19	2021-03-31	Merck Sharp & Dohme Corp.	Factor ixa inhibitors
GB201300304D0 (en)	2013-01-08	2013-02-20	Kalvista Pharmaceuticals Ltd	Benzylamine derivatives
GB2510407A (en)	2013-02-04	2014-08-06	Kalvista Pharmaceuticals Ltd	Aqueous suspensions of kallikrein inhibitors for parenteral administration
JP6479763B2 (ja)	2013-03-25	2019-03-06	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
TWI633089B (zh)	2013-03-28	2018-08-21	拜耳製藥股份有限公司	經取代的酮基吡啶衍生物
CN105555767B (zh)	2013-07-23	2018-03-23	拜耳制药股份公司	取代的氧代吡啶衍生物及其作为因子xia/血浆的用途
UY35747A (es)	2013-09-26	2015-04-30	Bayer Pharma AG	Derivados sustituidos de fenilalanina
US20160244437A1 (en)	2013-09-26	2016-08-25	Bayer Pharma Aktiengesellschaft	Substituted phenylalanine derivatives
US20160237045A1 (en)	2013-09-26	2016-08-18	Bayer Pharma Aktiengesellschaft	Substituted phenylalanine derivatives
UY35745A (es)	2013-09-26	2015-04-30	Bayer Pharma AG	Derivados sustituidos de fenilalanina
CN105745192A (zh)	2013-09-26	2016-07-06	拜耳制药股份公司	取代的苯丙氨酸衍生物
US20160280699A1 (en)	2013-09-26	2016-09-29	Bayer Pharma Aktiengesellschaft	Substituted phenylalanine derivatives
US20160237044A1 (en)	2013-09-26	2016-08-18	Bayer Pharma Aktiengesellschaft	Substituted phenylalanine derivatives
WO2015044169A1 (de)	2013-09-26	2015-04-02	Bayer Pharma Aktiengesellschaft	Substituierte phenylalanin-derivate
WO2015047973A1 (en)	2013-09-27	2015-04-02	Merck Sharp & Dohme Corp.	FACTOR XIa INHIBITORS
US20160257668A1 (en)	2013-10-07	2016-09-08	Merck Sharp & Dohme Corp.	Factor XIa Inhibitors
JP6337750B2 (ja)	2013-11-22	2018-06-06	小野薬品工業株式会社	化合物
WO2015107724A1 (ja)	2014-01-14	2015-07-23	大日本住友製薬株式会社	縮合５－オキサゾリジノン誘導体
NO2760821T3 (zh)	2014-01-31	2018-03-10
ES2687498T3 (es)	2014-01-31	2018-10-25	Bristol-Myers Squibb Company	Macrociclos con grupos P2¿ heterocíclicos como inhibidores del factor XIa
CA2938884C (en)	2014-02-07	2024-02-13	eXIthera Pharmaceuticals Inc.	Substituted azetidine compounds and their use as factor xia or kallikrein inhibitors
US9944643B2 (en)	2014-02-11	2018-04-17	Merck Sharp & Dohme Corp.	Factor XIa inhibitors
WO2015123090A1 (en)	2014-02-11	2015-08-20	Merck Sharp & Dohme Corp.	Factor xia inhibitors
WO2015123091A1 (en)	2014-02-11	2015-08-20	Merck Sharp & Dohme Corp.	Factor xia inhibitors
WO2015120777A1 (zh)	2014-02-14	2015-08-20	四川海思科制药有限公司	一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用
SG11201607267SA (en)	2014-03-07	2016-09-29	Biocryst Pharm Inc	Human plasma kallikrein inhibitors
US9969724B2 (en)	2014-04-16	2018-05-15	Merck Sharp & Dohme Corp.	Factor IXa inhibitors
US9808445B2 (en)	2014-04-16	2017-11-07	Merck Sharp & Dohme Corp.	Factor IXa inhibitors
GB201409202D0 (en) *	2014-05-23	2014-07-09	Ffei Ltd	Improvements in imaging microscope samples
KR20150136294A (ko)	2014-05-27	2015-12-07	주식회사 레고켐 바이오사이언스	인자 ＸＩａ 억제 활성을 가지는 신규한 화합물
KR20170005871A (ko)	2014-05-28	2017-01-16	머크 샤프 앤드 돔 코포레이션	인자 XIa 억제제
ES2712886T3 (es)	2014-09-24	2019-05-16	Bayer Pharma AG	Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa
US9453018B2 (en) *	2014-10-01	2016-09-27	Bristol-Myers Squibb Company	Pyrimidinones as factor XIa inhibitors
NO2721243T3 (zh) *	2014-10-01	2018-10-20
KR102525392B1 (ko)	2014-12-10	2023-04-24	오노 야꾸힝 고교 가부시키가이샤	디히드로인돌리지논 유도체
US10160750B2 (en)	2015-06-19	2018-12-25	Bristol-Myers Squibb Company	Diamide macrocycles as factor XIa inhibitors

2015
- 2015-01-30 ES ES15705860.3T patent/ES2687498T3/es active Active
- 2015-01-30 KR KR1020247003206A patent/KR20240017118A/ko not_active Ceased
- 2015-01-30 NZ NZ761182A patent/NZ761182A/en unknown
- 2015-01-30 DK DK15705860.3T patent/DK3099687T3/en active
- 2015-01-30 PE PE2020002136A patent/PE20210470A1/es unknown
- 2015-01-30 HU HUE15705860A patent/HUE040226T2/hu unknown
- 2015-01-30 HR HRP20181339TT patent/HRP20181339T1/hr unknown
- 2015-01-30 US US15/115,327 patent/US20170002006A1/en not_active Abandoned
- 2015-01-30 EP EP21192647.2A patent/EP3988549A1/en active Pending
- 2015-01-30 SM SM20180505T patent/SMT201800505T1/it unknown
- 2015-01-30 UY UY0001035971A patent/UY35971A/es not_active Application Discontinuation
- 2015-01-30 IL IL307212A patent/IL307212A/en unknown
- 2015-01-30 PE PE2016001274A patent/PE20161069A1/es unknown
- 2015-01-30 EP EP15705428.9A patent/EP3099686B1/en active Active
- 2015-01-30 EA EA201691471A patent/EA030222B1/ru not_active IP Right Cessation
- 2015-01-30 KR KR1020227021266A patent/KR102631769B1/ko active Active
- 2015-01-30 ES ES18174593T patent/ES2893251T3/es active Active
- 2015-01-30 IL IL322255A patent/IL322255A/en unknown
- 2015-01-30 CN CN201911001057.2A patent/CN110845498B/zh active Active
- 2015-01-30 EP EP18174593.6A patent/EP3392249B1/en active Active
- 2015-01-30 JP JP2016549277A patent/JP6464176B2/ja active Active
- 2015-01-30 JP JP2016549279A patent/JP6505727B2/ja active Active
- 2015-01-30 KR KR1020167023481A patent/KR102413453B1/ko active Active
- 2015-01-30 TW TW104103366A patent/TWI688564B/zh active
- 2015-01-30 BR BR112016015717-6A patent/BR112016015717B1/pt active IP Right Grant
- 2015-01-30 CN CN201580006495.1A patent/CN105980384B/zh active Active
- 2015-01-30 SG SG11201606209PA patent/SG11201606209PA/en unknown
- 2015-01-30 PL PL15705860T patent/PL3099687T3/pl unknown
- 2015-01-30 CA CA2937739A patent/CA2937739C/en active Active
- 2015-01-30 MX MX2016009230A patent/MX377545B/es active IP Right Grant
- 2015-01-30 LT LTEP15705860.3T patent/LT3099687T/lt unknown
- 2015-01-30 NZ NZ723762A patent/NZ723762A/en unknown
- 2015-01-30 WO PCT/US2015/013654 patent/WO2015116886A1/en not_active Ceased
- 2015-01-30 TW TW111149560A patent/TWI859674B/zh active
- 2015-01-30 RS RS20181028A patent/RS57659B1/sr unknown
- 2015-01-30 EP EP15705860.3A patent/EP3099687B1/en active Active
- 2015-01-30 UY UY0001040230A patent/UY40230A/es not_active Application Discontinuation
- 2015-01-30 US US15/115,314 patent/US9777001B2/en active Active
- 2015-01-30 PT PT15705860T patent/PT3099687T/pt unknown
- 2015-01-30 SG SG10201908467R patent/SG10201908467RA/en unknown
- 2015-01-30 TW TW109105925A patent/TWI790421B/zh active
- 2015-01-30 WO PCT/US2015/013652 patent/WO2015116885A1/en not_active Ceased
- 2015-01-30 TW TW104103305A patent/TW201613922A/zh unknown
- 2015-01-30 UY UY0001035975A patent/UY35975A/es active IP Right Grant
- 2015-01-30 CN CN201580017440.0A patent/CN106132962B/zh active Active
- 2015-01-30 ES ES15705428T patent/ES2784841T3/es active Active
- 2015-01-30 SI SI201530317T patent/SI3099687T1/en unknown
- 2015-01-30 AU AU2015210904A patent/AU2015210904C1/en active Active
- 2015-01-30 MY MYPI2016702666A patent/MY190429A/en unknown
- 2015-01-30 CN CN202310156065.4A patent/CN116987080A/zh active Pending
- 2015-01-30 IL IL298983A patent/IL298983B2/en unknown
2016
- 2016-06-24 PH PH12016501249A patent/PH12016501249B1/en unknown
- 2016-07-14 MX MX2020012520A patent/MX2020012520A/es unknown
- 2016-07-26 IL IL246964A patent/IL246964B/en active IP Right Grant
- 2016-07-29 CL CL2016001933A patent/CL2016001933A1/es unknown
- 2016-08-30 ZA ZA2016/06011A patent/ZA201606011B/en unknown
2018
- 2018-09-28 CY CY181101000T patent/CY1120702T1/el unknown
2019
- 2019-01-07 JP JP2019000516A patent/JP6630004B2/ja active Active
- 2019-03-27 JP JP2019060181A patent/JP6854067B2/ja active Active
- 2019-08-13 AU AU2019216617A patent/AU2019216617B2/en active Active
2020
- 2020-01-30 IL IL272377A patent/IL272377B2/en unknown
2021
- 2021-02-26 PH PH12021550418A patent/PH12021550418A1/en unknown
- 2021-03-12 JP JP2021039989A patent/JP7325464B2/ja active Active
- 2021-06-15 AU AU2021203968A patent/AU2021203968B2/en active Active
2023
- 2023-06-14 AU AU2023203695A patent/AU2023203695A1/en not_active Abandoned
- 2023-08-01 JP JP2023125512A patent/JP2023133468A/ja active Pending
2025
- 2025-03-17 AU AU2025201886A patent/AU2025201886A1/en active Pending

Also Published As

Publication number	Publication date
CA2937739A1 (en)	2015-08-06
PH12016501249A1 (en)	2016-08-15
IL298983B1 (en)	2023-11-01
BR112016015717A2 (pt)	2017-08-08
LT3099687T (lt)	2018-09-10
NZ723762A (en)	2023-03-31
TWI688564B (zh)	2020-03-21
MX377545B (es)	2025-03-10
BR112016015717A8 (pt)	2018-05-02
TWI790421B (zh)	2023-01-21
CY1120702T1 (el)	2019-12-11
CN106132962B (zh)	2018-09-07
AU2023203695A1 (en)	2023-07-06
EA030222B1 (ru)	2018-07-31
IL307212A (en)	2023-11-01
ZA201606011B (en)	2018-05-30
PH12016501249B1 (en)	2022-01-21
SI3099687T1 (en)	2018-08-31
WO2015116886A1 (en)	2015-08-06
EP3988549A1 (en)	2022-04-27
IL298983B2 (en)	2024-03-01
IL272377A (en)	2020-03-31
IL298983A (en)	2023-02-01
JP2019094354A (ja)	2019-06-20
DK3099687T3 (en)	2018-10-22
JP6505727B2 (ja)	2019-04-24
AU2015210904A1 (en)	2016-09-15
IL322255A (en)	2025-09-01
PH12021550418A1 (en)	2021-11-15
AU2019216617B2 (en)	2021-03-18
WO2015116885A1 (en)	2015-08-06
KR20160113267A (ko)	2016-09-28
IL272377B1 (en)	2023-01-01
JP2019077704A (ja)	2019-05-23
EP3099686B1 (en)	2020-03-11
CN110845498A (zh)	2020-02-28
JP2023133468A (ja)	2023-09-22
MX2020012520A (es)	2021-02-16
SMT201800505T1 (it)	2018-11-09
AU2019216617A1 (en)	2019-09-05
KR102631769B1 (ko)	2024-02-01
UY40230A (es)	2023-08-15
HUE040226T2 (hu)	2019-02-28
EP3392249A1 (en)	2018-10-24
IL246964A0 (en)	2016-09-29
EP3099687A1 (en)	2016-12-07
AU2025201886A1 (en)	2025-04-03
US20170002006A1 (en)	2017-01-05
CA2937739C (en)	2024-04-16
EP3099686A1 (en)	2016-12-07
EA201691471A1 (ru)	2016-12-30
ES2784841T3 (es)	2020-10-01
EP3099687B1 (en)	2018-07-04
JP6630004B2 (ja)	2020-01-15
JP2017504641A (ja)	2017-02-09
CN110845498B (zh)	2023-02-17
TW202037595A (zh)	2020-10-16
CL2016001933A1 (es)	2017-03-24
JP6464176B2 (ja)	2019-02-06
MX2016009230A (es)	2016-10-03
JP2017504642A (ja)	2017-02-09
CN106132962A (zh)	2016-11-16
AU2021203968A1 (en)	2021-07-08
AU2021203968B2 (en)	2023-03-30
TW201615639A (zh)	2016-05-01
PL3099687T3 (pl)	2018-12-31
PT3099687T (pt)	2018-10-19
ES2893251T3 (es)	2022-02-08
ES2687498T3 (es)	2018-10-25
IL246964B (en)	2020-02-27
US20170096429A1 (en)	2017-04-06
JP6854067B2 (ja)	2021-04-07
SG11201606209PA (en)	2016-08-30
BR112016015717B1 (pt)	2023-04-04
CN105980384A (zh)	2016-09-28
PE20210470A1 (es)	2021-03-08
CN105980384B (zh)	2019-11-15
UY35975A (es)	2015-07-31
KR20240017118A (ko)	2024-02-06
HRP20181339T1 (hr)	2018-12-28
TW202340188A (zh)	2023-10-16
UY35971A (es)	2015-07-31
JP2021088610A (ja)	2021-06-10
KR20220093390A (ko)	2022-07-05
RS57659B1 (sr)	2018-11-30
AU2015210904C1 (en)	2019-08-29
JP7325464B2 (ja)	2023-08-14
KR102413453B1 (ko)	2022-06-28
TWI859674B (zh)	2024-10-21
EP3392249B1 (en)	2021-08-25
CN116987080A (zh)	2023-11-03
IL272377B2 (en)	2023-05-01
AU2015210904B2 (en)	2019-05-16
SG10201908467RA (en)	2019-10-30
MY190429A (en)	2022-04-21
NZ761182A (en)	2023-04-28
PE20161069A1 (es)	2016-10-22
US9777001B2 (en)	2017-10-03

Publication	Publication Date	Title
PH12021550418A1 (en)	2021-11-15	Macrocycles with hetrocyclic p2` groups as factor xia inhibitors
PH12020500195A1 (en)	2021-02-08	Pyrimidinones as factor xia inhibitors
MX2016009385A (es)	2016-09-16	Inhibidores macrociclicos del factor xia condensados con heterociclicos.
MX2015000919A (es)	2015-09-21	Dihidropiridona p1 como inhibidores del factor xia.
MX2015000892A (es)	2015-04-17	Dihidropiridona p1 como inhibidores del factor xia.
PH12012501589A1 (en)	2012-10-22	Macrocycles as factor xia inhibitors
EA201490418A1 (ru)	2014-05-30	Новые макроциклические соединения в качестве ингибиторов фактора xia
TN2014000155A1 (en)	2015-09-30	Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
PH12016502378A1 (en)	2017-02-20	Substituted dihydroisoquinolinone compounds
TH170796A (th)	2017-11-23	พิริมิดีนในฐานะเป็นตัวยับยั้งแฟคเตอร์ xia